Précis: Low-dose oral contraceptives appeared to be effective in reducing ovarian cancer risk
The risk of ovarian cancer can be reduced by 50% or more in unselected women with long-term use of oral contraceptives (Am J Epidemiol 1992 Nov 15; 136(10): 1184-203). An oral contraceptive agent is appealing as a possible preventive treatment, because these agents are well tolerated and their side effects are known. In this study, the researchers assessed the risk of ovarian cancer in women taking the newer, lower-dose preparations of estrogen and progestin.
The oral contraceptive use of 767 women who were diagnosed with epithelial ovarian cancer was compared with that of 1,367 age-matched control subjects. Subjects' ages ranged between 20 and 89 years.
Approximate 40% reduction in risk of ovarian cancer was found among oral contraceptive users.
Risk reduction by oral contraceptive use continued for 30 or more years after use had stopped.
Lower-dose preparations of estrogen and progestin were just as effective as higher-dose ones in the risk reduction of ovarian cancer.
In this study, low-estrogen/low-progestin pills appeared to lower the risk of developing ovarian cancer to the same extent as higher dose pills used prior to 1972. It is important to know that oral contraceptive use has been associated with a small increase in the risk of breast cancer (J Natl Cancer Inst 1995 Jun 7; 87(11): 827-35). Patients should discuss with their physicians before they take oral contraceptives.
Oct 23, 2013 - Among women who are BRCA1/2 mutation carriers, the associations between ever use of oral contraceptives and ovarian and breast cancers are similar to those observed in the general population, according to research published online Oct. 21 in the Journal of Clinical Oncology.